Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer Genomics & Proteomics|April 27, 2011
Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplificationJ Krejci, M Pesek, P Grossmann, et al.
Neoplasma|December 25, 2012
Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapyO Fiala, M Pesek, J Finek, et al.
Neoplasma|October 17, 2012
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practiceO Fiala, M Pesek, J Finek, et al.
Anticancer Research|August 19, 2007
Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancerJ Safranek, L Holubec, O Topolcan, et al.
Neoplasma|August 3, 2013
Erlotinib in the treatment of advanced squamous cell NSCLCO Fiala, M Pesek, J Finek, et al.
Neoplasma|March 9, 2016
Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinibO Fiala, M Pesek, J Finek, et al.
Anticancer Research|July 15, 2009
Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary diseaseJ Safranek, M Pesta, L Holubec, et al.
Lung Cancer (Amsterdam, Netherlands)|February 27, 1999
Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II studyP Zatloukal, E Kanitz, P Magyar, et al.
Anticancer Research|July 26, 2007
Tumor markers in pleural effusionsO Topolcan, L Holubec, V Polivkova, et al.
Neoplasma|May 10, 2017
Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexedO Fiala, P Hosek, M Pesek, et al.
Pageof 4